Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.
Metrics: PDF 8264 views | HTML 5483 views | ?
James A. McCubrey1, Linda S. Steelman1, William H. Chappell1, Stephen L. Abrams1, Giuseppe Montalto2, Melchiorre Cervello3, Ferdinando Nicoletti4, Paolo Fagone4, Grazia Malaponte4, Maria C. Mazzarino4, Saverio Candido4, Massimo Libra4, Jörg Bäsecke5, Sanja Mijatovic6, Danijela Maksimovic-Ivanic6 Michele Milella7, Agostino Tafuri8 , Lucio Cocco9, Camilla Evangelisti10, Francesca Chiarini10, Alberto M. Martelli9,10
1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA
2 Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy
3 Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia Molecolare “Alberto Monroy”, Palermo, Italy
4 Department of Biomedical Sciences, University of Catania, Catania, Italy
5 Department of Medicine, University of Göttingen, Göttingen, Germany
6 Department of Immunology, Instititue for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia
7 Regina Elena National Cancer Institute, Rome, Italy
8 Sapienza, University of Rome, Department of Cellular Biotechnology and Hematology, Rome, Italy
9 Department of Biomedical and Neuromotor Sciences, Università di Bologna, Bologna, Italy
10 Institute of Molecular Genetics, National Research Council-Rizzoli Orthopedic Institute, Bologna, Italy
James A. McCubrey, email:
Keywords: Targeted Therapy, Therapy Resistance, Mutations, Raf, Akt, PI3K, mTOR
Received: August 12, 2012, Accepted: September 17, 2012, Published: September 20, 2012
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Certain components of these pathways, RAS, NF1, BRAF, MEK1, DUSP5, PP2A, PIK3CA, PIK3R1, PIK3R4, PIK3R5, IRS4, AKT, NFKB1, MTOR, PTEN, TSC1, and TSC2 may also be activated/inactivated by mutations or epigenetic silencing. Upstream mutations in one signaling pathway or even in downstream components of the same pathway can alter the sensitivity of the cells to certain small molecule inhibitors. These pathways have profound effects on proliferative, apoptotic and differentiation pathways. Dysregulation of components of these cascades can contribute to: resistance to other pathway inhibitors, chemotherapeutic drug resistance, premature aging as well as other diseases. This review will first describe these pathways and discuss how genetic mutations and epigenetic alterations can result in resistance to various inhibitors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.